糜蛋白酶联合阿莫西林克拉维酸钾治疗儿童急性化脓性扁桃体炎疗效观察

摘要

Objective To analyze the clinical efficacy of chymotrypsin combined with amoxicillin clavulanate potassium on pediatric acute suppurative tonsillitis. Methods 110 cases of acute suppurative tonsillitis children were selected and divided into the control group and the observation group according to the random number table method, 55 cases in each group. The control group was given amoxicillin clavulanate potassium, and the observation group received chymotrypsin combined with amoxicillin clavulanate potassium. The clinical efficacy, improvement of symptoms and signs, and adverse reactions of the two groups were compared and analyzed. Results The total efficiency rate of the observation group ( 96. 36% ) was significantly higher than the control group ( 69. 09% ) , and the difference was statistically significant ( P < 0. 05 ) . Sore throat improvement time was ( 2. 35 ± 0. 21 ) d, subsided time of the amygdala secretion was ( 2. 56 ± 0. 33 ) d, temperature recovery time was ( 1. 58 ± 0. 09 ) d and pharyngeal hyperemia subsided time was ( 3. 78 ± 0. 46 ) d in the observation group, which were significantly lower than the control group with ( 3. 42 ± 0. 36 ) d, ( 3. 78 ± 0. 52 ) d, ( 2. 78 ± 0. 16 ) d, ( 5. 49 ± 0. 78 ) d, and the difference was statistically significant ( P < 0. 05 ) . The incidence rate of adverse reaction in the observation group ( 3. 64% ) was significantly lower than the control group ( 30. 91% ) , and the difference was statistically significant ( P < 0. 05 ) . Conclusion Chymotrypsin combined with amoxicillin clavulanate potassium in treating pediatric acute suppurative tonsillitis has signifi-cant efficacy, can relieve the clinical symptoms with less adverse reactions, which is worthy of clinical promotion.%目的：探讨糜蛋白酶联合阿莫西林克拉维酸钾治疗急性化脓性扁桃体炎患儿的临床疗效。方法选取收治的化脓性扁桃体炎症急性发作患儿110例，按照随机数字表法分为对照组和观察组，各55例。对照组给予阿莫西林克拉维酸钾治疗，观察组给予糜蛋白酶联合阿莫西林克拉维酸钾治疗，对比分析两组患者的临床治疗效果、症状体征改善以及不良反应发生情况。结果观察组总有效率为96．36%，与对照组的69．09%相比明显较高，差异有统计学意义（ P<0．05）。观察组咽痛好转时间、扁桃体分泌物消退时间、体温恢复时间及咽部充血消退时间分别为（2．35±0．21）d，（2．56±0．33）d，（1．58±0．09）d，（3．78±0．46）d，与对照组的（3．42±0．36）d，（3．78±0．52）d，（2．78±0．16）d，（5．49±0．78）d相比明显较低，差异有统计学意义（ P<0．05）。观察组不良反应发生率为3．64%，与对照组的30．91%相比明显较低，差异有统计学意义（ P<0．05）。结论糜蛋白酶联合阿莫西林克拉维酸钾治疗儿童急性化脓性扁桃体炎疗效显著，可缓解临床症状，不良反应较少，值得临床推广。